Maarten L. Janmaat

3.2k citations

28 papers · 2.4k indexed · 1 hit paper · h-index 17

Oncology top 2%
Molecular Biology top 10%
Radiology, Nuclear Medicine and Imaging top 2%
Immunology top 5%
Pulmonary and Respiratory Medicine top 5%

Co-authors: Paul W.H.I. Parren Janice M. Reichert Aran F. Labrijn Giuseppe Giaccone José Antonio Rodríguez Frank A.E. Kruyt Mariëlle I. Gallegos-Ruiz Tuna Mutis
Topics: Monoclonal and Polyclonal Antibodies Research (10 papers)Lung Cancer Treatments and Mutations (6 papers)Phagocytosis and Immune Regulation (4 papers)
Cited by: Oncology Radiology, Nuclear Medicine and Imaging Immunology
Journals: Nature Medicine Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: Netherlands United States Denmark

In The Last Decade

Maarten L. Janmaat

27 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bispecific antibodies: a mechanistic review of the pipeline

2019 887 citations Aran F. Labrijn, Maarten L. Janmaat et al. Nature Reviews Drug Discovery profile →

Peers

Countries citing papers authored by Maarten L. Janmaat

Since Specialization

Citations

This map shows the geographic impact of Maarten L. Janmaat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maarten L. Janmaat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maarten L. Janmaat more than expected).

Fields of papers citing papers by Maarten L. Janmaat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maarten L. Janmaat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maarten L. Janmaat. The network helps show where Maarten L. Janmaat may publish in the future.

Co-authorship network of co-authors of Maarten L. Janmaat

This figure shows the co-authorship network connecting the top 25 collaborators of Maarten L. Janmaat. A scholar is included among the top collaborators of Maarten L. Janmaat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maarten L. Janmaat. Maarten L. Janmaat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity 2023 ·EBioMedicine ·Ida H. Hiemstra,Kim C. M. Santegoets,Maarten L. Janmaat,Bart E.C.G. de Goeij,(unknown),(unknown),Péter Boross,(unknown),Sieto Bosgra,(unknown),(unknown),Dennis Verzijl,Richard G. Hibbert,Kristine A. Frerichs,Tuna Mutis,Niels W.C.J. van de Donk,Tahamtan Ahmadi,David Satijn,A. Kate Sasser,Esther C.W. Breij	18
2	Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models 2022 ·Life Science Alliance ·Kristel Kemper,(unknown),Péter Boross,Mischa Houtkamp,Theo S. Plantinga,(unknown),Saskia M. Burm,Maarten L. Janmaat,Louise A. Koopman,Edward N. van den Brink,(unknown),Dennis Verzijl,Patrick Engelberts,David Satijn,A. Kate Sasser,Esther C.W. Breij	3
3	Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies 2022 ·Blood ·Simone C. Oostindie,Mir Farshid Alemdehy,Maarten L. Janmaat,Jenny Meerding,Kristel Kemper,Patrick Engelberts,Bart E.C.G. de Goeij,David Satijn,A. Kate Sasser,Esther C.W. Breij	6
4	Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade 2021 ·Cancer Research ·Julia Boshuizen,Nora Pencheva,Oscar Krijgsman,(unknown),Patricia Garrido Castro,Beaunelle de Bruijn,Maarten A. Ligtenberg,(unknown),David W. Vredevoogd,Ji‐Ying Song,Nils L. Visser,Georgi Apriamashvili,Maarten L. Janmaat,Theo S. Plantinga,Patrick Franken,Mischa Houtkamp,Andreas Lingnau,Maria Jure‐Kunkel,Daniel S. Peeper	48
5	Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models 2020 ·Blood ·Ida H. Hiemstra,Maarten L. Janmaat,Péter Boross,(unknown),(unknown),(unknown),Sieto Bosgra,(unknown),(unknown),Laurens P. Kil,A. Kate Sasser,Tahamtan Ahmadi,David Satijn,Esther C.W. Breij	0
6	Bispecific antibodies: a mechanistic review of the pipelinebreakdown → 2019 ·Nature Reviews Drug Discovery ·Aran F. Labrijn,Maarten L. Janmaat,Janice M. Reichert,Paul W.H.I. Parren	887
7	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer 2019 ·JCI Insight ·Louise A. Koopman,Mikkel G. Terp,Gijs G. Zom,Maarten L. Janmaat,Kirstine Jacobsen,(unknown),(unknown),Ulf Forssmann,(unknown),Nora Pencheva,Andreas Lingnau,M Zipeto,Paul W.H.I. Parren,Esther C.W. Breij,Henrik J. Ditzel	46
8	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors 2018 ·Nature Medicine ·Julia Boshuizen,Louise A. Koopman,Oscar Krijgsman,Aida Shahrabi,(unknown),Maarten A. Ligtenberg,David W. Vredevoogd,Kristel Kemper,Thomas Kuilman,Ji‐Ying Song,Nora Pencheva,Jens Mortensen,Marnix Geukes Foppen,Elisa A. Rozeman,Christian U. Blank,Maarten L. Janmaat,David Satijn,Esther C.W. Breij,Daniel S. Peeper,Paul W.H.I. Parren	164
9	Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys 2017 ·Scientific Reports ·Mario Losen,Aran F. Labrijn,Vivianne van Kranen-Mastenbroek,Maarten L. Janmaat,Krista G. Haanstra,Frank J. Beurskens,Tom Vink,Margreet Jonker,Bert A. ‘t Hart,Marina Mané-Damas,Peter Molenaar,Pilar Martínez‐Martínez,(unknown),Janine Schuurman,Marc H. De Baets,Paul W.H.I. Parren	8
10	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond 2016 ·Immunological Reviews ·Niels W.C.J. van de Donk,Maarten L. Janmaat,Tuna Mutis,Jeroen J. Lammerts van Bueren,Tahamtan Ahmadi,A. Kate Sasser,Henk M. Lokhorst,Paul W.H.I. Parren	237
11	Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers. 2015 ·Journal of Clinical Oncology ·Esther C.W. Breij,Sandra Verploegen,Andreas Lingnau,Edward N. van den Brink,Maarten L. Janmaat,Mischa Houtkamp,Wim K. Bleeker,David Satijn,Paul W.H.I. Parren	6
12	Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines 2009 ·Anti-Cancer Drugs ·(unknown),(unknown),(unknown),Maarten L. Janmaat,Epie Boven	26
13	Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels 2007 ·Biochemical Pharmacology ·(unknown),(unknown),(unknown),(unknown),Maarten L. Janmaat,Godefridus J. Peters,Epie Boven	34
14	Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling 2005 ·Molecular Pharmacology ·Maarten L. Janmaat,José Antonio Rodríguez,José Jimeno,Frank A.E. Kruyt,Giuseppe Giaccone	81
15	P-485 EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancer 2005 ·Lung Cancer ·Giuseppe Giaccone,Maarten L. Janmaat,Mariëlle Gallegos Ruiz,July Rodríguez,T. Lechevalier,Nicholas Thatcher,Egbert F. Smit,(unknown),Jean‐Charles Soria	3
16	A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer 2005 ·Journal of Clinical Oncology ·Giuseppe Giaccone,T. Lechevalier,Nicholas Thatcher,Egbert F. Smit,Maarten L. Janmaat,J. Rodríguez,D. Oulid-Aïssa,J.C. Soria	25
17	Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cells 2005 ·International Journal of Cancer ·Maarten L. Janmaat,José Antonio Rodríguez,Mariëlle I. Gallegos-Ruiz,Frank A.E. Kruyt,Giuseppe Giaccone	130
18	560 Kahalalide F (KF) induces apoptosis-independent cell death that involves ErbB3 downregulation and inhibition of Akt signalling 2004 ·European Journal of Cancer Supplements ·Maarten L. Janmaat,Frank A.E. Kruyt,José Jimeno,(unknown),Giuseppe Giaccone	1
19	The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. 2003 ·PubMed ·Maarten L. Janmaat,Giuseppe Giaccone	67
20	Evidence that the dephosphorylation of Ser535 in the ∊-subunit of eukaryotic initiation factor (eIF) 2B is insufficient for the activation of eIF2B by insulin 2002 ·Biochemical Journal ·Xuemin Wang,Maarten L. Janmaat,Anne Beugnet,F. Paulin,Christopher G. Proud	39

About Maarten L. Janmaat

Maarten L. Janmaat is a scholar working on Oncology, Physiology and Radiology, Nuclear Medicine and Imaging, having authored 28 papers that have together received 2.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (10 papers), Lung Cancer Treatments and Mutations (6 papers) and Phagocytosis and Immune Regulation (4 papers). The work is most often cited by research in Oncology (1.3k citations), Radiology, Nuclear Medicine and Imaging (726 citations) and Immunology (567 citations). Maarten L. Janmaat has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Paul W.H.I. Parren, Janice M. Reichert, Aran F. Labrijn, Giuseppe Giaccone, José Antonio Rodríguez, Frank A.E. Kruyt, Mariëlle I. Gallegos-Ruiz, Tuna Mutis, Tahamtan Ahmadi and Niels W.C.J. van de Donk. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact